SI
SRPT icon

Symmetry Investments’s Sarepta Therapeutics SRPT Stock Holding History

Symmetry Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,200
Closed -$1.71M – 152
2022
Q4 		$1.71M Buy
+13,200
New +$1.53M 0.46% 43

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Symmetry Investments's SRPT Position: Q1 2023 in Review

Symmetry Investments sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 13,200 shares — an estimated $1.71M sold.

Symmetry Investments first reported a position in SRPT in Q4 2022 and held it in 1 quarter. The position peaked at $1.71M in Q4 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • Symmetry Investments reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Symmetry Investments sold 13,200 Sarepta Therapeutics shares in Q1 2023, an estimated $1.71M.
  • Symmetry Investments first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 1 quarter.
  • Symmetry Investments's Sarepta Therapeutics position peaked at $1.71M in Q4 2022.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Symmetry Investments's 13F filing for Q1 2023, filed 15 May 2023.